+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 18Years +
All Genders
ID05756569

Phase II Study of Enfortumab Vedotin and Pembrolizumab for Advanced or Metastatic Variant Bladder Cancer

Led by Emory University · Updated on 2026-07-29

25

Participants Needed

4

Research Sites

52 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the combination of enfortumab vedotin and pembrolizumab in patients with bladder cancer of variant histology that is locally advanced or has spread to other parts of the body. This phase II trial aims to assess how well this treatment works by measuring tumor response and safety over time. The study also explores biological markers to better understand treatment effects. Participants receive enfortumab vedotin and pembrolizumab intravenously during the trial. Imaging scans like CT or MRI and blood collections are performed regularly to monitor the disease and treatment impact. The trial includes assessments up to two years to evaluate tumor response, progression-free survival, overall survival, and treatment safety. During the study, participants undergo scheduled visits for drug administration, imaging scans, blood draws, and questionnaires. Researchers monitor tumor response using standard imaging criteria and track side effects and survival outcomes. The involvement may last up to two years with ongoing safety and efficacy evaluations throughout this period.

CONDITIONS

Brief Title

Enfortumab Vedotin Plus Pembrolizumab for the Treatment of Locally Advanced or Metastatic Bladder Cancer of Variant Histology

Research Team

J

Jacqueline Brown, MD

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here